SPRB - NASDAQ
Spruce Biosciences, Inc.
$53.16
+8.1%Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
At a Glance
Live SnapshotSpruce Biosciences, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Spruce Biosciences, Inc. Cash Flow Statement
SPRB • NASDAQ
| Spruce Biosciences, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||
-39M | -53M | -47.9M | -46.2M | -42.3M | -29.5M | -13.1M | -9.9M | |
21K | 46K | 70K | 429K | 68K | 36K | 12K | 1K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -446K | 0.0 | |
2.6M | 5.3M | 4.6M | 0.0 | 4M | 755K | 196K | 101K | |
3.8M | 249K | -404K | 2.9M | 434K | 66K | 446K | -1.6M | |
-724K | -8.6M | 10.4M | 1.1M | 2M | 1.2M | 263K | 1.2M | |
-33.3M | -56M | -33.3M | -41.7M | -35.9M | -27.5M | -12.6M | -8.6M | |
INVESTING ACTIVITIES | ||||||||
(0.0) | (0.0) | -7K | -8K | -93K | -74K | -4K | (0.0) | |
(0.0) | (0.0) | -11.9M | -36.8M | -79.1M | (0.0) | (0.0) | (0.0) | |
0.0 | 0.0 | 67.7M | 60.5M | 0.0 | 0.0 | 0.0 | 0.0 | |
(0.0) | (0.0) | (55.8M) | (23.7M) | -79.2M | -74K | -4K | (0.0) | |
FINANCING ACTIVITIES | ||||||||
50.1M | 246K | 53.6M | -201K | 0.0 | 93.4M | 0.0 | 0.0 | |
-2.1M | -1.6M | -1.6M | 0.0 | 220K | 0.0 | 4.5M | 0.0 | |
-4.5M | -246K | -2.9M | -40K | 423K | 51K | 0.0 | 0.0 | |
43.5M | -1.6M | 49.1M | -241K | 643K | 181M | 12.4M | 0.0 | |
CASH FLOW SUMMARY | ||||||||
0.0 | 0.0 | 0.0 | 187K | 0.0 | 0.0 | 0.0 | 0.0 | |
10.2M | -57.6M | 71.6M | -18M | -114.4M | 153.4M | -188K | -8.6M | |
38.8M | 96.3M | 24.7M | 42.7M | 157.4M | 3.9M | 4.1M | 12.7M | |
48.9M | 38.8M | 96.4M | 24.7M | 43M | 157.4M | 3.9M | 4.1M | |
-33.3M | -56M | -33.3M | -41.7M | -36M | -27.6M | -12.6M | -8.6M |
SEC Filings
SPRB - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 26, 2026 | May 21, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 22, 2026 | April 20, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 09, 2026 | April 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 20, 2026 | March 16, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 09, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 09, 2026 | March 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 05, 2026 | February 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 07, 2026 | 2026 |
Related Guides
Continue your SPRB research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.